Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease. The company also develops product candidates, which are in preclinical stage, including ATH-1019/ATH-1020 for neuropsychiatric conditions; and ATH-1018 for peripheral nervous system disorders, such as neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
IPO Year: 2020
Exchange: NASDAQ
Website: athira.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/19/2024 | $5.00 → $0.50 | Outperform → Neutral | Mizuho |
| 9/4/2024 | Buy → Neutral | Rodman & Renshaw | |
| 9/4/2024 | Buy → Neutral | BTIG Research | |
| 9/4/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 8/19/2024 | $22.00 | Buy | Rodman & Renshaw |
| 10/17/2022 | $20.00 | Mkt Perform → Mkt Outperform | JMP Securities |
| 7/7/2022 | $6.00 | Buy | Mizuho |
| 6/23/2022 | $36.00 → $5.00 | Buy → Hold | Stifel |
| 6/23/2022 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 6/23/2022 | $32.00 → $3.00 | Buy → Hold | Jefferies |
Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development On-track to enable initiation of a clinical trial in ALS patients in late 2025 BOTHELL, Wash., May 13, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that the Company will present data from a Phase 1 clinical trial of ATH-1105 in healthy volunteers at the 4th Annual ALS drug Development Summit taking place from May 1
Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25 On-track to enable dosing ALS patients in late 2025 BOTHELL, Wash., May 09, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended March 31, 2025, and provided recent pipeline and business updates. "We continue to focus our efforts on advancing ATH-1105 as a potential therapy for ALS. ATH-1105 has shown encouraging ev
Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS) On-track to enable dosing ALS patients in 2025 BOTHELL, Wash., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the year ended December 31, 2024, and provided recent pipeline and business updates. "We look forward to the opportunity to continue to advance ATH-1105 as a potential therapy for ALS, which in various preclinical models has demonstrated a consistent ability to
BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today presented preclinical data highlighting target engagement and neuroprotective effects of ATH-1105 in human motor neurons at the Motor Neurone Disease Association's 35th International Symposium on ALS/MND, taking place Dec. 6-8, 2024, in Montreal, Canada. "The preclinical data presented demonstrate for the first time the neuroprotective effects of ATH-1105 in human models of ALS, including human iPSC-derived motor neurons expressing the SOD1-A4V mutation," said Kevin
BOTHELL, Wash., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended September 30, 2024, and provided recent pipeline and business updates. "We are pleased to be continuing the advancement of ATH-1105 as a potential treatment for ALS. This novel, oral, next-generation HGF-modulating drug candidate has improved blood-brain-barrier penetration and pharmacokinetic properties. Specifically, preclinically ATH-1105 has shown a consistent ability in various ALS models to reduce plasma neurofi
BOTHELL, Wash., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that results from the Phase 2/3 LIFT-AD clinical trial of fosgonimeton to treat Alzheimer's disease (AD) will be presented at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) taking place October 29 - November 1, 2024, in Madrid, Spain. Presentation Details: Title: Fosgonimeton for the Treatment of Alzheimer's Disease; Efficacy and Safety Results from the LIFT-AD TrialSession: Oral Communications: OC2 Date/Time: Tuesday, October 29 at 5:10 p
ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical trial with completion expected by year end 2024 and commencement of dosing of ALS patients expected in 2025 Company announces cost containment measures in alignment with focus on advancing ATH-1105 BOTHELL, Wash., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that following the topline data readout from the Phase 2/3 LIFT-AD clinical trial of fosgonimeton to
LIFT-AD trial did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function (ADCS-ADL23) In pre-specified subgroups of patients with moderate Alzheimer's disease or who are APOE4 carriers, fosgonimeton showed a numerically greater treatment effect All biomarkers associated with Alzheimer's disease pathology showed changes with fosgonimeton treatment consistent with the broad neuroprotective mechanism of HGF modulation Athira to host live webcast today at 4:30 PM Eastern time BOTHELL, Wash., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing sm
Fosgonimeton mitigated amyloid-β-induced toxicity, lowered pTau levels and reduced disruption of protein clearance mechanisms that may contribute to pTau pathology Fosgonimeton treatment, alone and in combination with lecanemab, protected cultures of primary neurons from the toxic effects of amyloid-β BOTHELL, Wash., July 31, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented new preclinical data further highlighting the therapeutic potential of fosgonimeton at the Alzheimer's Association International Con
Reporting of Topline Results Targeted by End of Third Quarter 2024 Results to be presented in oral presentation at Clinical Trials on Alzheimer's Disease (CTAD) on October 29, 2024, in Madrid, Spain BOTHELL, Wash., July 09, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the completion of dosing for the last patient in the Phase 2/3 LIFT-AD clinical trial evaluating fosgonimeton in people with mild-to-moderate Alzheimer's disease (AD). The Company is now targeting to report topline results from the LIFT-AD trial by the end
Recently, on June 25, 2024, Director Romano Kelly A bought $100,051 worth of shares in Athira Pharma Inc. This transaction involved acquiring 42,400 units at $2.36 per share, resulting in a significant increase in direct ownership by 111% to 80,715 units. The purchase was disclosed in the SEC Form 4 filing. Insider buying is often considered a bullish signal as insiders may have insights into the company's future performance. It's essential to analyze this insider purchase in conjunction with previous insider transactions to identify any patterns or trends. Taking into account the information from the SEC filings, several other insiders at Athira Pharma Inc. have also been active in the sto
On track to report topline data from ACT-AD Phase 2 Alzheimer's disease study in 2Q22 Expect to complete enrollment in LIFT-AD Phase 3 Alzheimer's disease study in 3Q22 Conference call today at 4:30 pm Eastern time BOTHELL, Wash., March 24, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the company's financial results for the year ended December 31, 2021 and provided a clinical update. "We entered 2022 with strong momentum from the solid foundation established throughout 2021 and have made considerable progress across
BOTHELL, Wash., March 17, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced it will report financial results for the fourth quarter and full year ended December 31, 2021 and provide a business update on Thursday, March 24, 2022 following the close of the U.S. financial markets. Athira will host a conference call to discuss these results on Thursday, March 24, 2022 at 4:30 pm Eastern time (1:30 pm Pacific time). In order to participate in the conference call, please dial 833-614-1520 (domestic) or 516-575-8710 (internationa
Special Committee of the Board of Directors has concluded its investigation of Dr. Leen Kawas's Doctoral ResearchConference call to be held October 21, 2021 at 4:30 pm ET BOTHELL, Wash., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Mark Litton, Ph.D., M.B.A. as Chief Executive Officer of Athira. Dr. Litton succeeds Dr. Leen Kawas, who has resigned from her position as the Company's President and Chief Executive Officer and as a member of the Company's Board of Directors. Dr. Litton will also
4 - Athira Pharma, Inc. (0001620463) (Issuer)
4 - Athira Pharma, Inc. (0001620463) (Issuer)
SC 13G/A - Athira Pharma, Inc. (0001620463) (Subject)
SC 13G - Athira Pharma, Inc. (0001620463) (Subject)
SC 13D/A - Athira Pharma, Inc. (0001620463) (Subject)
SC 13G - Athira Pharma, Inc. (0001620463) (Subject)
SC 13D/A - Athira Pharma, Inc. (0001620463) (Subject)
SC 13G/A - Athira Pharma, Inc. (0001620463) (Subject)
SC 13G - Athira Pharma, Inc. (0001620463) (Subject)
SC 13G/A - Athira Pharma, Inc. (0001620463) (Subject)
SC 13G/A - Athira Pharma, Inc. (0001620463) (Subject)
SC 13G/A - Athira Pharma, Inc. (0001620463) (Subject)
4/A - Athira Pharma, Inc. (0001620463) (Issuer)
4 - Athira Pharma, Inc. (0001620463) (Issuer)
4 - Athira Pharma, Inc. (0001620463) (Issuer)
4 - Athira Pharma, Inc. (0001620463) (Issuer)
4 - Athira Pharma, Inc. (0001620463) (Issuer)
4 - Athira Pharma, Inc. (0001620463) (Issuer)
4 - Athira Pharma, Inc. (0001620463) (Issuer)
4 - Athira Pharma, Inc. (0001620463) (Issuer)
4 - Athira Pharma, Inc. (0001620463) (Issuer)
4 - Athira Pharma, Inc. (0001620463) (Issuer)
10-Q - Athira Pharma, Inc. (0001620463) (Filer)
8-K - Athira Pharma, Inc. (0001620463) (Filer)
SCHEDULE 13G - Athira Pharma, Inc. (0001620463) (Subject)
8-K - Athira Pharma, Inc. (0001620463) (Filer)
DEFA14A - Athira Pharma, Inc. (0001620463) (Filer)
DEF 14A - Athira Pharma, Inc. (0001620463) (Filer)
PRE 14A - Athira Pharma, Inc. (0001620463) (Filer)
S-8 - Athira Pharma, Inc. (0001620463) (Filer)
10-K - Athira Pharma, Inc. (0001620463) (Filer)
8-K - Athira Pharma, Inc. (0001620463) (Filer)
Mizuho downgraded Athira Pharma from Outperform to Neutral and set a new price target of $0.50 from $5.00 previously
Rodman & Renshaw downgraded Athira Pharma from Buy to Neutral
BTIG Research downgraded Athira Pharma from Buy to Neutral
JMP Securities downgraded Athira Pharma from Mkt Outperform to Mkt Perform
Rodman & Renshaw initiated coverage of Athira Pharma with a rating of Buy and set a new price target of $22.00
JMP Securities upgraded Athira Pharma from Mkt Perform to Mkt Outperform and set a new price target of $20.00
Mizuho initiated coverage of Athira Pharma with a rating of Buy and set a new price target of $6.00
Stifel downgraded Athira Pharma from Buy to Hold and set a new price target of $5.00 from $36.00 previously
JMP Securities downgraded Athira Pharma from Mkt Outperform to Mkt Perform
Jefferies downgraded Athira Pharma from Buy to Hold and set a new price target of $3.00 from $32.00 previously
BOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Javier San Martin, M.D., as Chief Medical Officer. Dr. San Martin brings more than 25 years of drug development experience and a proven track record leading cross-functional product teams to drive global development and commercialization strategies for multiple drugs across large and rare diseases with significant unmet medical need. "We are pleased to welcome Javier to the team and are confident his insights and guidance will be i
BOTHELL, Wash., May 22, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Andrew Gengos as Chief Financial Officer and Chief Business Officer, effective immediately. Mr. Gengos replaces Glenna Mileson, who is retiring after serving as Athira's Chief Financial Officer for eight years. "On behalf of the entire Athira team, we thank Glenna for her many years of service, particularly for her stewardship during our transition to a publicly traded company, and wish her well in retirement," said Mark Litton, Ph.D
New, Independent, Shareholder-Centric Directors are Needed to Ensure ATH-1017's Significant Potential is Realized and Reverse Destruction of Shareholder Value by Athira's Current Board Launches Campaign Website with Additional Information for Shareholders: www.SaveAthira.com Urges Athira Shareholders to VOTE their BLUE Proxy Card TODAY Richard A. (Ric) Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc. (NASDAQ:ATHA) ("Athira" or the "Company"), today released a detailed presentation to Athira's shareholders demonstrating the need for immediate change on the Company's Board of Directors (the "Board"
Director Nominees Are Ric Kayne, ~4.8% Athira Shareholder, and George Bickerstaff, Former CFO of Novartis Pharma AG Sends Open Letter to Shareholders Highlighting Urgent Need for Change Following Board's Hasty Decision to Force the Resignation of Co-Founder & Former CEO Without Adequate Succession Plan Details Rushed Appointment of CEO Dr. Mark Litton, Who Lacks Relevant Experience to Oversee Pivotal Clinical Trials, Falsified His Credentials and Has Overseen Significant Destruction of Shareholder Value Believes New Management and Shareholder Centric Directors Are Required to Provide Proper Oversight of ATH-1017 Clinical Trials to Maximize Likelihood of Achieving Successful Outcome Rich
BOTHELL, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Michael A. Panzara, M.D., MPH to its Board of Directors. Dr. Panzara currently serves as Chief Medical Officer, Head of Therapeutics Discovery and Development at Wave Life Sciences (NASDAQ:WVE) and brings over 20 years of biopharmaceutical industry experience developing therapies for neurological disorders, including in leadership roles at Sanofi Genzyme and Biogen. "Mike is a recognized and experienced leader in the development
BOTHELL, Wash., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Grant Pickering to its Board of Directors. Mr. Pickering is Chief Executive Officer, co-founder and member of the Board of Directors at Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. "Grant is an accomplished life sciences leader with considerable experience across all stages of development and commercialization of new med
- Initiated open label extension for LIFT-AD and ACT-AD trials of ATH-1017 allowing for an additional six months of treatment - ACT-AD and LIFT-AD are actively recruiting; topline data of ACT-AD are targeted by first half 2022 and topline data from LIFT-AD are targeted by end of 2022 BOTHELL, Wash., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today reported its financial results for the second quarter ended June 30, 2021 and provided an update on the company's operations. "In the second quarter
BOTHELL, Wash., June 14, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Rachel Lenington as Chief Technology Officer, Head of Product Development Strategy, effective June 14. Ms. Lenington brings more than 20 years of biopharmaceutical leadership experience at leading organizations including Seagen Inc, the Bill & Melinda Gates Foundation and Amgen with roles spanning R&D decision making, drug development and commercialization and partnership management. "Rachel is adept at successfully integrating sci
BOTHELL, Wash., June 01, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Mark Worthington as the company's General Counsel, effective June 1. "We have worked with Mark for many years and are excited he is now joining Athira. He brings a wealth of experience providing legal and strategic business counsel to private and public companies including life science companies," said Leen Kawas, Ph.D., President and Chief Executive Officer at Athira. "As our General Counsel, Mark will be integrally involved in Ath
BOTHELL, Wash., March 08, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Barbara Kosacz to its Board of Directors. Ms. Kosacz is Chief Operating Officer and General Counsel at Kronos Bio, Inc., a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that transform the lives of those affected by cancer. “Barbara will add to the existing expertise of our Board, bringing her vast experience in working strategically with biopharma companies and adding a new perspectiv